FERRING PHARMS INC
SpecialtyFERRING PHARMS INC is a specialty pharmaceutical company focused on Metabolic. Key products include CLENPIQ.
FERRING PHARMS INC at a Glance
- Strong track record with 84% execution quality across 129 trials
- Fast trial execution (18 months median completion)
FERRING PHARMS INC's Key Drugs
FERRING PHARMS INC's core commercial portfolio centers on CLENPIQ, spanning Metabolic — its most strategically important drugs approved in the last 15 years.
FERRING PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for FERRING PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
FERRING PHARMS INC's Therapeutic Areas
FERRING PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FERRING PHARMS INC's Top Competitors
FERRING PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
FERRING PHARMS INC Pipeline Snapshot
Active clinical trials for FERRING PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CLENPIQ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 62/72 completed
- • Speed: 18 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges